Cholecystokinin-2 Receptor Agonist 177Lu-PP-F11N for Radionuclide Therapy of Medullary Thyroid Carcinoma - Results of the Lumed Phase 0a Study
Metadata only
Date
2020-04Type
- Journal Article
Citations
Cited null times in
Web of Science
Cited 8 times in
Scopus
ETH Bibliography
yes
Altmetrics
Publication status
publishedExternal links
Journal / series
The Journal of Nuclear MedicineVolume
Pages / Article No.
Publisher
Society of Nuclear MedicineSubject
cholecystokinin 2 receptor targeting; peptide receptorradionuclide therapy; 177Lu-PP-F11N; theranosticsOrganisational unit
03688 - Schibli, Roger / Schibli, Roger
03688 - Schibli, Roger / Schibli, Roger
More
Show all metadata
Citations
Cited null times in
Web of Science
Cited 8 times in
Scopus
ETH Bibliography
yes
Altmetrics